Setmelanotide, a selective agonist of the MC4R, is approved by the FDA and EMA for the treatment of obesity and control of hunger in Bardet-Biedl Syndrome or biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in affected children above age 2 years-old [103]. Here, POMC is linked to obesity disorder.